Form D · Biotechnology
Centrexion Therapeutics Corp
Boston, MA · CIK 0001592052
Offering snapshot reported Jan 8, 2024 · SEC filing
- Reported sold
- $3.26M Offering amount: $12.9M
- Investors reported
- 116 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 28, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 8, 2024 | Initial | $3,255,467 | No comparison | 116 | SEC filing |
| Nov 27, 2023 | Initial | $2,300,000 | No comparison | 2 | SEC filing |
| Jul 11, 2023 | Amendment | $10,280,238 | $0vs Jun 29, 2023 | 124 | SEC filing |
| Jun 29, 2023 | Initial | $10,280,238 | No comparison | 124 | SEC filing |
| Aug 11, 2022 | Amendment | $29,140,000 | $5,390,000vs Jun 28, 2022 | 47 | SEC filing |
| Jun 28, 2022 | Amendment | $23,750,000 | $7,275,000vs Jun 8, 2022 | 43 | SEC filing |
| Jun 8, 2022 | Initial | $16,475,000 | No comparison | 25 | SEC filing |
| Jan 26, 2021 | Initial | $13,500,000 | No comparison | 17 | SEC filing |
| Jan 2, 2018 | Initial | $69,566,532 | No comparison | 67 | SEC filing |
| May 23, 2017 | Initial | $5,285,000 | No comparison | 40 | SEC filing |
| Jan 5, 2017 | Initial | $16,564,789 | No comparison | 14 | SEC filing |
| Jun 21, 2016 | Initial | $11,163,500 | No comparison | 61 | SEC filing |
| Apr 15, 2016 | Initial | $6,905,000 | No comparison | 21 | SEC filing |
| Mar 14, 2016 | Initial | $10,516,500 | No comparison | 25 | SEC filing |
| Dec 3, 2013 | Amendment | $14,728,886 | $0vs Nov 22, 2013 | 98 | SEC filing |
| Dec 3, 2013 | Initial | $8,750,000 | No comparison | 20 | SEC filing |
| Nov 22, 2013 | Initial | $14,728,886 | No comparison | 98 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $1.28M (estimated)
- Finders' fees
- $0
- Form D file number
- 021-501850
The compensation payable to Maxim Group LLC under the total offering amount is estimated to consist of (i) a cash fee (listed above) and (ii) a warrant to purchase up to 855,470 shares of Centrexion's common stock.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Maxim Group LLC | 120708 |
Source: Form D, filed Jan 8, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Sol Barer | Director |
| Sol Barer, Ph.D. | Director |
| Gregg Beloff | Executive |
| Isaac Blech | Director |
| Kerrie L. Brady | Executive |
| James N. Campbell | Director, Executive |
| James N. Campbell, M.D. | Director, Executive |
| Colin Hill | Director |
| Dezhi Kang, Ph.D. | Director |
| Jeffrey B. Kindler | Director, Executive |
| J.C. Lopez, M.D. | Director |
| J. C. Lopez, M.D. | Director |
| Daniel Mendelson | Director |
| Sara Nayeem | Director |
| Arnold Oronsky | Director |
| Randall M. Stevens | Executive |
| Joseph R. Swedish | Director |
| Shawn Tomasello | Director |
| Michael J. Ward | Executive |
| Peter Wirth | Director |
| Stella Xu | Director |
| Shengda Zan | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
200 State Street 6 Th Floor
Boston, MA, 02109
Boston, MA, 02109